Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies
Christine M. Minnar, Paul L. Chariou, Lucas A. Horn, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 6, pp. e004561-e004561
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Kun Pang, Zhenduo Shi, Liuya Wei, et al.
Drug Resistance Updates (2022) Vol. 66, pp. 100907-100907
Closed Access | Times Cited: 117
A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
Ginette S. Santiago-Sánchez, Kellsye P. Fabian, James W. Hodge
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 15
Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine
Christine M. Minnar, Grace Lui, James L. Gulley, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 9
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
Jessica Konen, Haoyi Wu, Don L. Gibbons
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 520-536
Closed Access | Times Cited: 8
Advanced progress in the genetic modification of the oncolytic HSV-1 virus
Mi Zhou, Zhenyu Shen
Frontiers in Oncology (2025) Vol. 14
Open Access | Times Cited: 1
Targeting the epigenome to reinvigorate T cells for cancer immunotherapy
Dian Xiong, Lu Zhang, Zhi‐Jun Sun
Military Medical Research (2023) Vol. 10, Iss. 1
Open Access | Times Cited: 20
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment
María del Mar Maldonado, Jeffrey Schlom, Duane H. Hamilton
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 10, pp. 3349-3362
Open Access | Times Cited: 19
Targeting CXCL9/10/11–CXCR3 axis: an important component of tumor-promoting and antitumor immunity
Minjie Pan, Xiao‐Shan Wei, Xuan Xiang, et al.
Clinical & Translational Oncology (2023) Vol. 25, Iss. 8, pp. 2306-2320
Closed Access | Times Cited: 17
Monocyte/Macrophage‐Mediated Transport of Dual‐Drug ZIF Nanoplatforms Synergized with Programmed Cell Death Protein‐1 Inhibitor Against Microsatellite‐Stable Colorectal Cancer
Xietao Ye, Yuping Liu, Liangyin Wei, et al.
Advanced Science (2024) Vol. 11, Iss. 38
Open Access | Times Cited: 6
Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response
Hong Zheng, Minghao Wang, Shiyu Zhang, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 14, pp. 4689-4708
Open Access | Times Cited: 15
Identification of a gene score related to antigen processing and presentation machinery for predicting prognosis in head and neck squamous cell carcinoma and its potential implications for immunotherapy
Xueliang Fang, Qingjie Li, Li Wang, et al.
Clinical & Translational Oncology (2024)
Closed Access | Times Cited: 4
Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy
Zhihao Hu, Shuqing Li, Haiqi He, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
A novel HVEM-Fc recombinant protein for lung cancer immunotherapy
Yu Yao, B. Li, Jing Wang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
PD-1/CTLA-4 antibody AK104 in advanced solid tumors after PD/PD-L1 treatment failure: A retrospective cohort study
Jun Yi, Herbert Yu, Yun Shu, et al.
Medicine (2025) Vol. 104, Iss. 10, pp. e41548-e41548
Open Access
Monoclonal antibody immune therapy response instrument for stratification and cost-effective personalized approaches in 3PM-guided pan cancer management
Salem Baldi, Mohammed Alnaggar, Maged AL-Mogahed, et al.
The EPMA Journal (2025)
Closed Access
Immunocytokines based on IL-12 for cancer therapy: Enhancing efficacy and reducing toxicity
Uxue Beloki, Laura Salaberry, Ángela Covo-Vergara, et al.
International review of cell and molecular biology (2025)
Closed Access
The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers
Ecem Kalemoglu, Yash Jani, Kübra Canaslan, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Enhancing immunotherapy efficacy against MHC-I deficient triple-negative breast cancer using LCL161-loaded macrophage membrane-decorated nanoparticles
Wen Zhang, Yi­hui Zhai, Ying Cai, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 7, pp. 3218-3231
Open Access | Times Cited: 3
Myeloid effector cells in cancer
Pieter J. Schol, Marit J. van Elsas, Jim Middelburg, et al.
Cancer Cell (2024) Vol. 42, Iss. 12, pp. 1997-2014
Closed Access | Times Cited: 3
Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12
Nicole J. Toney, Margaret E. Gatti‐Mays, Nicholas Tschernia, et al.
International Immunopharmacology (2023) Vol. 116, pp. 109736-109736
Open Access | Times Cited: 7
Human IL-35 Inhibits the Bioactivity of IL-12 and Its Interaction with IL-12Rβ2
Najmus Mahfooz, Marlena R. Merling, Tiffany A. Claeys, et al.
ImmunoHorizons (2023) Vol. 7, Iss. 6, pp. 431-441
Open Access | Times Cited: 7
Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Hengzhou Zhu, Wenyue Zhao, Haoyan Chen, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma
Tingting Xu, Yuan Fang, Yunru Gu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 10, pp. e010077-e010077
Open Access | Times Cited: 2
Uncovering the interleukin‐12 pharmacokinetic desensitization mechanism and its consequences with mathematical modeling
Jonathon DeBonis, Omid Veiseh, Oleg A. Igoshin
CPT Pharmacometrics & Systems Pharmacology (2024)
Open Access | Times Cited: 2
The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions
Ning Jia, Yutao Wang, Zijia Tao
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top